文献速递肿瘤 PET/CT放射性药物与辐射防护

司美格鲁肽首次给药后五天18F-FDG PET/CT显示多器官副作用一例

18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot.
PubMed 文献 · Clin Nucl Med · 2026-02-03

一例60岁转移性乳腺癌女性在首次司美格鲁肽给药后5天行18F-FDG PET/CT疗效评估,除肿瘤表现外,显像显示异常胃潴留、胆囊、结肠及肾脏摄取模式,提示司美格鲁肽所致胃轻瘫、胆囊炎、结肠炎及脱水相关可能急性肾损伤,临床评估证实上述怀疑,支持治疗并停用司美格鲁肽后症状缓解。

要点

  • 18F-FDG PET/CT可显示司美格鲁肽相关多器官副作用影像表现。
  • 单次司美格鲁肽给药后即可出现胃轻瘫、胆囊炎、结肠炎及可能急性肾损伤。
  • 核医学医师需识别GLP-1受体激动剂相关副作用及其影像征象。

核心结论

  • 首次单次司美格鲁肽给药后18F-FDG PET/CT可显示多器官副作用,包括胃潴留、胆囊、结肠及肾脏异常摄取。

研究设计与样本

  • 为个案报道,描述一例60岁转移性乳腺癌女性在首次司美格鲁肽给药后5天行18F-FDG PET/CT评估治疗反应。

主要发现

  • PET/CT除肿瘤表现外显示异常胃潴留、胆囊、结肠及肾脏摄取模式。
  • 影像提示司美格鲁肽诱导的胃轻瘫、胆囊炎、结肠炎及脱水继发可能急性肾损伤,临床评估证实怀疑。
  • 支持治疗并停用司美格鲁肽后症状缓解。

临床怎么用

  • 核医学医师阅片时应结合用药史,识别GLP-1受体激动剂相关副作用在18F-FDG PET/CT上的多器官表现。

局限性

  • 为单例个案报道,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment. Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration. Suspicions were confirmed by clinical evaluation. Symptoms resolved after supportive therapy and withholding of semaglutide. To our knowledge, this is the first report of multi-organ side effects seen on 18 F-FDG PET/CT following a single semaglutide dose administration, emphasizing the need for nuclear medicine physicians to recognize glucagon-like peptide-1 receptor agonist medication-related side effects and their imaging manifestations.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Triumbari EKA, Lorusso M, Cirillo F, et al. 18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot. Clin Nucl Med. 2026. PMID: 41650160. doi:10.1097/RLU.0000000000006360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。